Zobrazeno 21 - 30
of 114
pro vyhledávání: '"Andrea Pirzkall"'
Autor:
Evelyn Yanez, Andrea Pirzkall, Joseph A. Ware, Kari M. Morrissey, Shuguang Ma, Nicholas Siebers, Roland Morley, Stephanie Royer-Joo, Hoa Le, Lori Joas, Julia Suchomel, Xiaorong Liang, Rui Zhu, Edward Yost, Laurent Salphati
Publikováno v:
British Journal of Clinical Pharmacology
AIMS Navoximod (GDC-0919, NLG-919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were to assess navoximod's absolut
Autor:
Anna Olsson-Brown, Mohammed M. Milhem, P.K. Bommareddy, Andrea Pirzkall, S. Samakoglu, Francesca Aroldi, L. Menezes, Adel Samson, Jiaxin Niu, Robert Coffin, Jason Chesney, Ari M. Vanderwalde, Scott Baum, Brendan D. Curti, Mark R. Middleton, T.L. Bowles, Terence Duane Rhodes, Joseph J. Sacco, K.J. Harrington, Douglas Earl Laux
Publikováno v:
Annals of Oncology. 32:S903-S904
Autor:
Pablo Nenclares, Praveen K. Bommareddy, Kevin J. Harrington, Anna Olsson-Brown, Henry Castro, Joseph J. Sacco, Tze Chan, Robert S. Coffin, Imran Saleem, Mark R. Middleton, Francesca Aroldi, Andrea Pirzkall, Isla Leslie
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundRP2 is a first-in-class, enhanced potency oncolytic herpes simplex virus (HSV) -1 expressing GM-CSF, a fusogenic protein (GALV-GP R-), and an anti-CTLA-4 antibody-like molecule that is being tested in an open-label, multicenter, phase 1 stu
Autor:
Claire F. Verschraegen, Susan Navia, Andrea Pirzkall, Andrew Poklepovic, Jason J. Luke, Frances A. Collichio, Praveen K. Bommareddy, Wanxing Chai-Ho, Diana Bolotin, Michael R. Migden, Robert S. Coffin, Henry Castro, Trisha Wise-Draper, Katy K. Tsai, Douglas Earl Laux, Gregory A. Daniels, Meenal Kheterpal, Jose Lutzky
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A580-A580
BackgroundSolid organ transplantation (SOT) has emerged as an important lifesaving procedure for patients with a wide range of end-organ diseases characterized by dysfunction or specific organ function failure. SOT rejection is a major complication r
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Autor:
Adel Samson, Victoria Roulstone, Andrea Pirzkall, Robert M. Conry, Ari M. Vanderwalde, Anna C. Pavlick, Joseph J. Sacco, Jiaxin Niu, Joan Kyula, Robert S. Coffin, Lavita Menezes, Mohammed M. Milhem, Douglas E Laux, Terence Duane Rhodes, Selda Samakoglu, Pablo Nenclares, Scott Baum, Brendan D. Curti, Suzanne Thomas, Tawnya L. Bowles, Jason Chesney, Alex Deterding, Francesca Aroldi, Anna Olsson-Brown, Kevin J. Harrington, Praveen K. Bommareddy, Mark R. Middleton
Publikováno v:
Cancer Research. 81:LB180-LB180
Introduction:RP1 and RP2 are novel, enhanced potency oncolytic versions of HSV1 engineered to express human GM-CSF and the gibbon ape leukemia virus membrane R- glycoprotein (GALV-GP R-), providing constitutive fusion activity and increased immunogen
Autor:
Amy V. Kapp, Stephanie Royer-Joo, Lori J. Wirth, Antonio Jimeno, X. Wang, Tanguy Y. Seiwert, Jean-Pascal Machiels, Bruce McCall, Pol Specenier, Feby Mardjuadi, Elicia Penuel, Paul Clement, Andrea Pirzkall
Publikováno v:
Cancer. 122:3803-3811
BACKGROUND This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor re
Autor:
Omar Kabbarah, Thomas Sandmann, C Rumpel, Mark R. Lackner, Garret Hampton, Elicia Penuel, Richard Bourgon, Lukas C. Amler, Yulei Wang, Eloisa Fuentes, Christopher A. Moskaluk, Ling Fu, Josep Tabernero, Kwame Okrah, Andrea Pirzkall, Kimberly Walter, Shan Lu, Xueping Qu, Henry F. Frierson
Publikováno v:
Oncogene
Key molecular drivers that underlie transformation of colonic epithelium into colorectal adenocarcinoma (CRC) are well described. However, the mechanisms through which clinically targeted pathways are activated during CRC progression have yet to be e
Autor:
Mario R. Mautino, Ray S. Lin, John Edward Janik, Eugene P. Kennedy, Andrea Pirzkall, Charles J. Link, Xiaorong Liang, David H. Munn, Sami Mahrus, Bruce McCall, Nicholas N. Vahanian, Laurent Salphati, Zhonglin Hao, Stephanie Royer-Joo, Asha Nayak-Kapoor, Samir N. Khleif, Lisa Marshall, Ramses F. Sadek, W. Jay Ramsey, Kari M. Morrissey, Robin Dobbins
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) i
Autor:
Lyndon Kim, Vanitha Ramakrishnan, Martin J. van den Bent, Tobias Walbert, Katie Wood, James Battiste, Timothy F. Cloughesy, David Schiff, Patrick Y. Wen, Song Mu, Vinay K. Puduvalli, Rachel Wei, Jian Campian, Bing Du, Andrea Pirzkall, Kent C. Shih
Publikováno v:
Neuro-Oncology. 20:vi17-vi18
DNA damage caused by TMZ or RT sensitizes tumors to PARP inhibitors, especially in highly replicating tumors (eg, GBM). Pamiparib is a selective PARP1/2 inhibitor with potent PARP trapping that can cross the blood-brain barrier and has shown synergis